@bellmatic I meant no offence and I apologizeI suspect that...

@bellmatic I meant no offence and I apologize

I suspect that there will be an opportunity (for everyone except T - sucker) to sell shares after successful P1a/b many multiples higher than we are now.

I do wonder, however, if your line of thinking is influenced moreso by the shareprice than the value of the IP.

Adding a successful P1a/b CPACS to Bisantrene is a significant event. This is something that has never happened before in cancer therapy.

Personally, a successful CPACS means I am well and truly on for the ride, and I think that is the smartest move because this kind of opportunity may never happen again in my lifetime.